Vaccination against cytomegalovirus

Archives of Virology, Supplement

Volumn , Issue 17, 2001, Pages 121-134

  Plotkin, S A ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOMEGALOVIRUS VACCINE; DNA VACCINE; GLYCOPROTEIN B, TYPE 1 HERPES SIMPLEX VIRUS; GLYCOPROTEIN H, CYTOMEGALOVIRUS; GLYCOPROTEIN H, HUMAN CYTOMEGALOVIRUS; LIVE VACCINE; VIRUS DNA; VIRUS ENVELOPE PROTEIN;

ANIMAL; CYTOMEGALIC INCLUSION BODY DISEASE; CYTOMEGALOVIRUS; FOWLPOX VIRUS; GENETIC RECOMBINATION; GENETICS; HUMAN; IMMUNOLOGY; PLASMID; REVIEW; VACCINATION;

ANIMALS; AVIPOXVIRUS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; CYTOMEGALOVIRUS VACCINES; DNA, VIRAL; HUMANS; PLASMIDS; RECOMBINATION, GENETIC; VACCINATION; VACCINES, ATTENUATED; VACCINES, DNA; VIRAL ENVELOPE PROTEINS;

EID: 0035236702     PISSN: 09391983     EISSN: None     Source Type: Journal    
DOI: 10.1007/978-3-7091-6259-0_13     Document Type: Article

References (70)

1. Adler SP (1996) Current prospects for immunization against cytomegaloviral disease. Infect Agents Dis 5: 29-35
2. Adler SP (1986) Molecular epidemiology of cytomegalovirus: evidence for viral transmission to parents from children infected at a day care center. Pediatr Infect Dis 5: 315-318
3. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis J 17: 200-206
4. Adler SP, Plotkin SA, Gonczol E, Cadoz M, Meric C, Wang JB, Dellamonica P, Best AM, Zahradnik J, Pincus S, Berencsi K, Cox WI, Gyulai Z (1999) A canarypox vector expressing cytomegalovirus (CMV) glycoprotein B primes for antibody responses to a live attenuated CMV vaccine (Towne). J Infect Dis 180: 843-846
5. Adler SP, Starr SE, Plotkin SA, Hempfling SH, Buis J, Manning ML, Best AM (1995) Immunity induced by primary human cytomegalovirus infection protects against secondary infection among women of childbearing age. J Infect Dis 171: 26-32
6. Adler SP, Hempfling SH, Starr SE, Plotkin SA, Riddell S (1998) Safety and immunogenicity of the Towne strain cytomegalovirus vaccine. Pediatr Infect Dis 17: 200-206
7. Balfour HH (1991) Prevention of cytomegalovirus disease in renal allograft recipients. Scand J Infect Dis 78: 88-93
8. Bennink JR, Yewdell JW, Smith GL, Moller C, Moss B (1984) Recombinant vaccinia virus primes and stimulates influenza haemagglutinin-specific cytotoxic T cells. Nature 311: 578-579
9. Britt WJ, Mach M (1996) Human cytomegalovirus glycoproteins. Intervirology 39: 401-412
10. Burian K, Endresz V, Gyulai Z (1999) Prevalence of the IE1-exon4-specific CTL in naturally seropositive healthy individuals. [Abstract] 7th International Cytomegalovirus Workshop, Brighton, UK, March 7-9
11. Burke RL (1991) Development of a Herpes simplex virus subunit glycoprotein vaccine for prophylactic and therapeutic use. J Infect Dis 13: S906-S911
12. Cha TA, Tom E, Kemble GW (1996) Human cytomegalovirus clinical isolates carry at least 19 genes not found in laboratory strains. J Virol 70: 78-83
13. Chou SW (1986) Acquisition of donor strains of cytomegalovirus by renal-transplant recipients. N Engl J Med 314: 1418-1423
14. Diamond DJ, York J, Sun JY, Wright CL, Forman SJ (1997) Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood 90: 1751-1767
15. Elek SD, Stern H (1974) Development of a vaccine against mental retardation caused by cytomegalovirus infection in utero. Lancet 1: 1-5
16. Endresz V, Kari L, Berencsi K, Kari C, Gyulai Z, Jeney C, Pincus S, Rodeck U, Meric C, Plotkin SA, Gonczol E (1999) Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphorprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization. Vaccine 17: 50-58
17. Excler JL, Plotkin SA (1997) The prime-boost concept applied to HIV preventive vaccines. AIDS 11: S127-S137
18. Fox JC, Kidd IM, Griffiths PD, Sweny P, Emery VC (1995) Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol 1995, 76: 309-319
19. Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S (1996) Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14: 428-434
20. Gonczol E, Berencsi K, Pincus S, Endresz V, Meric C, Paoletti E, Plotkin SA (1995) Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate. Vaccine 13: 1080-1085
21. Gonczol E, Ianocone J, Ho W, Starr S, Meignier B, Plotkin S (1990) Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine 8: 130-136
22. Gratacap-Cavallier B, Bosson JL, Morand P, Dutertre N, Chanzy B, Jouk PS, Vandekerckhove C, Cart-Lamy P, Seigneurin JM (1998) Cytomegalovirus seroprevalence in French pregnant women. Eur J Epidemiol 14: 147-152
23. Gupta R, Gonczol E, Manning ML, Starr S, Johnson B, Murphy GF, Plotkin SA (1993) Delayed type hypersensitivity to human cytomegalovirus. J Med Virol 39: 109-17
24. Gyulai Z, Pincus S, Cox B (1999) Canarypox-CMV-pp65 recombinant immunization of seronegative subjects elicits pp65 specific CTL precursors with a frequency comparable to pp65 specific frequency of naturally seropositive individuals. [Abstract] 7th International Cytomegalovirus Workshop, Brighton, UK, March 7-9
25. Henderson DA, Moss B (1999) Smallpox. In: Plotkin SA, Orenstein WA (eds) Vaccines. W. B. Saunders, Philadelphia, pp 74-97
26. Keay S, Baldwin B (1991) Anti-idiotype antibodies that mimic gp86 of human cytomegalovirus inhibit viral fusion but not attachment. J Virol 65: 5124-5128
27. Krech U, Konjajev Z, Jung M (1971) Congenital cytomegalovirus infection in siblings from consecutive pregnancies. Helv Paediatr Acta 26: 355-362
28. Li CR, Greenberg PD, Gilbert MJ, Goodrich JM, Riddell SR (1994) Recovery of HLA-restricted cytomegalovirus (CMV)-specific T-cell responses after allogeneic bone marrow transplant: correlation with CMV disease and effect of ganciclovir prophylaxis. Blood 83: 1971-1979
29. Liu H, Chou S, Sekulovich R, Duliege A-M, Burke RL (1997) A CMV glycoprotein gB subunit vaccine elicits cross neutralizing antibodies that cross neutralize clinical isolates. Abstract 43. Sixth International Cytomegalovirus Workshop. March 7-9, Perdido Beach, AL
30. Lucht E, Brytting M, Bjerregaard L (1998) Shedding of cytomegalovirus and herpesviruses 6,7, and 8 in saliva of human immunodeficiency virus type 1-infected patients and healthy controls. Clin Infect Dis 27: 137-141
31. Magno A, Smith GL, Moss B (1982) Vaccinia virus. A selectable eukaryotic cloning and expression vector. Proc Natl Acad Sci USA 79: 7415-7419
32. Marshall GS, Plotkin SA (1994) Progress toward developing a cytomegalovirus vaccine. Infect Dis Clinics N Am 4: 283-298
33. McLaughlin-Taylor E, Pande H, Forman SJ, Tanamachi B, Li CR, Zaia JA, Greenberg PD, Riddell SR (1994) Identification of the major late human cytomegalovirus matrix protein pp65 as a target antigen for CD8+ virus-specific cytotoxic T lymphocytes. J Med Virol 43: 103-110
34. Mitchell D, Holmes SJ, Burke RL, Sekulovich R, Tripathi M, Doyle M, Duliege AM (1997) Immunogenicity of a recombinant human cytomegalovirus (CMV) gB vaccine in toddlers. Sixth International Cytomegalovirus Workshop. March 5-9 (Abstract no. 50)
35. Mocarski ES Jr, Kemble GW (1996) Recombinant cytomegaloviruses for study of replication and pathogenesis. Intervirology 39: 320-330
36. Neff BJ, Weibel RE, Buynak EB, McAllen AA, Hillman MR (1979) Clinical and laboratory studies of live c cytomegalovirus vaccine Ad-169. Proc Soc Exp Biol Med 160: 32-37
37. Pande H, Campo K, Tanamachi B, Forman SJ, Zaia JA (1998) Direct DNA immunization of mice with plasmid DNA encoding the tegument protein pp65 (ppUL83) of human cytomegalovirus induces high levels of circulating antibody to the encoded protein. Scand J Infect Dis [Suppl] 99: 117-120
38. Panicali D, Paoletti E (1982) Construction of poxviruses as cloning vectores: Insertion of the thymidine kinase gene from herpes simplex virus into the DNA of infectious vaccinia virus. Proc Natl Acad Sci USA 79: 4927-4931
39. Pass RF, Hutto C, Ricks R, Cloud GA (1986) Increased rate of cytomegalovirus infection among parents of children attending day-care centers. N Engl J Med 314: 1414-1418
40. Pass R, Duliège AM, Sekulovich R, Boppana S, Hirabayashi S, Britt WJ, Burke RL (1997) Antibody response to a fourth dose of CMV gB vaccine in healthy adults. Abstract 157. Sixth International Cytomegalovirus Workshop. March 7-9: Perdido Beach, AL
41. Plotkin SA (1999) Cytomegalovirus. In: Plotkin SA, Orenstein WA (eds) Vaccines. Saunders, Philadelphia, pp 903-908
42. Plotkin SA, Cadoz M, Meignier B, Meric C, Leroy O, Excler JL, Tartaglia J, Paoletti E, Gonczol E, Chappuis G (1995) The safety and use of canarypox vectored vaccines. Dev Biol Stand 84: 165-170
43. Plotkin SA, Eagle H, Hayflick L, Ikic D, Koprowski H, Perkins F (1969) Serially cultured animal cells for the preparation of viral vaccines. Science 165: 1282
44. Plotkin SA, Farquhar J, Horberger E (1976) Clinical trials of immunization with the Towne 125 strain of human cytomegalovirus. J Infect Dis 134: 470-475
45. Plotkin SA, Furukawa T, Zygraich N, Huygelen C (1975) Candidate cytomegalovirus strain for human vaccination. Infect Immun 12: 521-527
46. Plotkin SA, Higgins R, Kurtz JB (1994) Multicenter trial of Towne strain attenuated virus vaccine in seronegative renal transplant recipients. Transplantation 58: 1176-1178
47. Plotkin SA, Huang ES (1985) Cytomegalovirus vaccine virus (Towne strain) does not induce latency. J Infect Dis 152: 395-397
48. Plotkin SA, Smiley ML, Friedman HM, Starr SE, Fleisher GR, Wlodaver C, Dafoe DC, Friedman AD, Grossman RA, Barker CF (1984) Towne-vaccine-induced prevention of cytomegalovirus disease after renal transplants. Lancet 1: 528-530
49. Plotkin SA, Starr SE, Friedman HM, Brayman K, Harris S, Jackson S, Tustin NB, Grossman R, Dafoe D, Barker C (1991) Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial. Ann Intern Med 114: 525-531
50. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Weibel RE (1989) Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge. J Infect Dis 159: 860-865
51. Plotkin SA, Starr SE, Friedman HM, Gonczol E, Brayman K (1990) Vaccines for the prevention of human cytomegalovirus infection. Rev Infect Dis [Suppl] 7: S827-S838
52. Porath A, McNutt RA, Smiley LM, Weigle KA (1990) Effectiveness and cost benefit of a proposed live cytomegalovirus vaccine in the prevention of congenital disease. Rev Infect Dis 12: 31-40
53. Qadri I, Navarro D, Paz P, Pereira L (1992) Assembly of conformation-dependent neutralizing domains on glycoprotein B of human cytomegalovirus. J Gen Virol 73: 2913-2921
54. Quinnan GV Jr, Delery MRA, Frederick WR, Epstein JS, Manischewitz JF, Jackson L, Ramsey KM, Mittal K, Plotkin SA (1984) Comparative virulence and immunogenicity of the Towne strain and a nonattenuated strain of cytomegalovirus. Ann Intern Med 101: 478-483
55. Rosenthal S, Stanberry LR, Biro FM, Slaoui M, Francotte M, Koutsoukos M, Hayes M, Bernstein DI (1997) Seroprevalence of Herpes simplex virus types 1 and 2 and cytomegalovirus in adolescents. Clin Infect Dis 24: 135-139
56. Rasmussen L, Morris S, Wolitz R, Dowling A, Fessell J, Holodniy M, Merigan TC (1994) Deficiency in antibody response to human cytomegalovirus glycoprotein gH in human immunodeficiency virus-infected patients at risk for cytomegalovirus retinitis. J Infect Dis 170: 673-677
57. Sinzger G, Jahn G (1996) Human cytomegalovirus cell tropism and pathogenesis. Intervirology 39: 302-319
58. Smiley ML, Wlodaver CG, Grossman RA, Barker CF, Perloff LJ, Tustin NB, Starr SE, Plotkin SA, Friedman HM (1985) The role of pretransplant immunity in protection. Transplantation 40: 157-161
59. Spaete RR (1991) A recombinant subunit vaccine approach to HCMV vaccine development. Transplant Proc 23: 90-96
60. Stagno S, Reynolds DW, Huang ES (1977) Congenital cytomegalovirus infection. N Engl J Med 296: 1254-1258
61. Sutter G, Wyatt LS, Foley P, Bennink JR, Moss B (1994) A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12: 1032-1040
62. Suwansirikul S, Rao N, Dowling JN, Ho M (1977) Primary and secondary cytomegalovirus infection. Arch Intern Med 137: 1036-1029
63. Taylor J, Meignier B, Tartaglia J, Languet B, VanderHoeven J, Franchini G, Trimarchi C, Paoletti E (1995) Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13: 539-549
64. Urban M, Klein M, Britt WJ, Hassfurther E, Mach M (1996) Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response. J Gen Virol 77: 1537-1547
65. Ulmer JB, Donnelly JJ, Parker SE, Rhodes GH, Feigner PL, Dwarki VJ, Gromkowski SH, Deck RR, DeWitt CM, Friedman A (1993) Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 259: 1745-1749
66. Walter EA, Greenberg PD, Gilbert MJ, Finch RJ, Watanabe KS, Thomas ED, Riddell SR (1982) Reconstruction of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 307: 7-13
67. Wang JB, Adler SP, Hempfling S, Burke RL, Duliege AM, Starr SE, Plotkin SA (1996) Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines. J Infect Dis 174: 387-392
68. Wills MR, Carmichael AJ, Mynard K, Jin X, Weekes MP, Plachter B, Sissons JG (1996) The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structural protein pp65: frequency, specificity, and T-cell receptor usage of pp65-specific CTL. J Virol 70: 7569-7579
69. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, Feigner PL (1990) Direct gene transfer into mouse muscle in vivo. Science 247: 1465-1468
70. Yamane Y, Furukawa T, Plotkin SA (1983) Supernatant virus release as a differentiating marker between low passage and vaccine strains of human cytomegalovirus. Vaccine 1: 25